North America Gastrointestinal Drugs Market Analysis, Size, and Share by 2027

North America Gastrointestinal Drugs Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Drug Class (Acid Neutralizers, Antidiarrheal and Laxatives, Anti-Inflammatory Drugs, Antiemetic and Antinauseants, Biologics, and Others); Route of Administration (Oral, and Parenteral); Application (Inflammatory Ulcerative Colitis, Crohn's Disease, Irritable Bowel Syndrome, Gastroenteritis, Celiac Disease, and Others); and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Country

Report Date : Nov 2020
Report Code : TIPRE00016278

Category : Life Sciences
Status : Published

Available Report Formats :
No. of Pages : 133

The North America gastrointestinal drugs market is expected to reach US$ 31,664.45 million by 2027 from US$ 21,292.53 million in 2019; it is estimated to grow at a CAGR of 5.2% from 2020 to 2027.

Rising prevalence of gastrointestinal (GI) diseases, and increase in development of biologics are the key factors driving the growth of gastrointestinal drugs. However, side effects associated with the drugs is the major factor hindering the Gastrointestinal Drugs market growth in North America.

Gastrointestinal (GI) disorders are the medical conditions related to the digestive system that affect the colon, small and large intestine, and rectum. The disorders include constipation, irritable bowel, ulcerative colitis, and peptic ulcer diseases. These disorders are characterized by various symptoms such as pain, bloating, diarrhea, nausea, and vomiting. These disorders constitute a large proportion of outpatients and frequent hospital visits. A wide range of GI drugs is commercially available in the market for the treatment of various conditions. Additionally, rising investments in the development of biologics and the emergence of a biosimilar are expected to drive the growth of the market in the forecast period.

Growing prevalence of IBD can be ascribed to poor nutritional choices, including a high intake of ultra-processed foods and trans-fats. Western countries, such as the US, and Canada, are witnessing a high GI incidence rate due to increasing obesity in the adult population and less consumption of dietary fibers. As per the Centers for Disease Control and Prevention, in 2018, the number of visits to physician offices with the digestive system's diseases as the primary diagnosis was 22.4 million in the US. The incidence and prevalence of IBS have increased in the last few decades. As per the International Foundation for Gastrointestinal Disorders, IBS is the most common functional GI disorder with a prevalence rate of 10–15%. There are around 2.4–3.5 million physician visits for IBS annually in the US. As per the Crohn’s & Colitis Foundation of America, IBS affects approximately 1.6 million Americans. Around 70,000 new cases of IBD are diagnosed every year in the US. Apart from the US, other countries are also witnessing increasing burden of chronic digestive diseases due to the aging population and lifestyle factors such as rising obesity and heavy alcohol consumption. Thus, the factors mentioned above are driving the adoption of GI drugs during the forecast period.

North America has been witnessing a growing number of COVID-19 cases since its outbreak. Supply chain disruptions associated with this pandemic situation will ultimately affect the sales of products for short period. However, the OTC supply of gastrointestinal drug has been continuous in the pandemic as medical shops are allowed to open though everything is locked down. Several companies are cutting their clinical trial activities in response to the COVID-19 pandemic. However, in long run, market is expected to boost the demand of gastrointestinal drugs in the forecasted period. Therefore, growing demand for the constipation treatment in North America in long-term period is likely to boost the growth of the constipation treatment market.

Mexico Gastrointestinal Drugs Market, Revenue and Forecast to 2027 (US$ Mn)

Inquire for Discount

Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Request discounts available for Start-Ups & Universities

NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SEGMENTATION

By Drug Class

Acid Neutralizers
Antidiarrheal and Laxatives
Anti-Inflammatory Drugs
Antiemetic and Antinauseants
Biologics
Others

By Route of Administration

Oral
Parenteral

By Application

Inflammatory Ulcerative Colitis
Crohn's Disease
Irritable Bowel Syndrome
Gastroenteritis
Celiac Disease
Others

By Distribution Channel

Retail Pharmacies
Hospital Pharmacies
Online Pharmacies

By Country

US
Canada
Mexico

Company Profiles

Johnson and Johnson Services, Inc.
Bausch Health
AbbVie Inc.
LEXICON PHARMACEUTICALS, INC
Takeda Pharmaceutical Company Limited

Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered

Drug Class, Route of Administration, Application, and Distribution Channel, and Country

Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope

US, Canada

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 North America Gastrointestinal Drugs Market – By Drug Class

1.3.2 North America Gastrointestinal Drugs Market – By Route of Administration

1.3.3 North America Gastrointestinal Drugs Market – By Application

1.3.4 North America Gastrointestinal drugs Market – By Distribution Channel

1.3.5 North America Gastrointestinal drugs Market – By Country

2. North America Gastrointestinal Drugs Market – Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. North America Gastrointestinal Drugs Market – Market Landscape

4.1 Overview

4.2 PEST Analysis

4.2.1 Gastrointestinal Drugs Market - North America PEST Analysis

4.3 Expert Opinion

5. North America Gastrointestinal Drugs Market - Key Market Dynamics

5.1 Key Market Drivers

5.1.1 Rise in Prevalence of Gastrointestinal (GI) Diseases

5.1.2 Increase in Development of Biologics

5.2 Market Restraints

5.2.1 Side Effects Associated With The Drugs

5.3 Market Opportunities

5.3.1 Increasing Investment in Research Activities and Growing Pipeline of GI Candidates

5.4 Future Trends

5.4.1 Emergence of Biosimilars

5.5 Impact Analysis

6. Gastrointestinal Drugs Market – North America Analysis

6.1 North America Gastrointestinal Drugs Market Revenue Forecasts and Analysis

7. North America Gastrointestinal Drugs Market Analysis And Forecasts To 2027 – By Drug Class

7.1 Overview

7.2 North America Gastrointestinal Drugs Market, By Drug Class 2019 & 2027 (%)

7.2.1 North America Gastrointestinal drugs Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)

7.3 Acid Neutralizers

7.3.1 Overview

7.3.2 North America Acid Neutralizers Market Revenue and Forecast to 2027 (US$ Mn)

7.4 Antidiarrheal and Laxatives

7.4.1 Overview

7.4.2 North America Antidiarrheal and Laxatives Market Revenue and Forecasts to 2027 (US$ Mn)

7.5 Anti-Inflammatory Drugs

7.5.1 Overview

7.5.2 North America Anti-Inflammatory Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

7.6 Antiemetic and Antinauseants

7.6.1 Overview

7.6.2 North America Antiemetic and Antinauseants Market Revenue and Forecast to 2027 (US$ Mn)

7.7 Biologics

7.7.1 Overview

7.7.2 North America Biologics Market Revenue and Forecasts to 2027 (US$ Mn)

7.8 Others

7.8.1 Overview

7.8.2 North America Others Market Revenue and Forecasts to 2027 (US$ Mn)

8. North America Gastrointestinal Drugs Market Analysis – By Route of Administration

8.1 Overview

8.2 North America Gastrointestinal Drugs Market, By Route of Administration 2019-2027 (%)

8.2.1 North America Gastrointestinal Drugs Market Revenue and Forecasts to 2027, By Route of Administration (US$ Mn)

8.3 Oral

8.3.1 Overview

8.3.2 North America Oral Market Revenue and Forecasts to 2027 (US$ Mn)

8.4 Parenteral

8.4.1 Overview

8.4.2 North America Parenteral Market Revenue and Forecasts to 2027 (US$ Mn)

9. North America Gastrointestinal Drugs Market Analysis – By Application

9.1 Overview

9.2 North America Gastrointestinal Drugs Market, By Application 2019-2027 (%)

9.2.1 North America Gastrointestinal Drugs Market Revenue and Forecasts to 2027, By Application (US$ Mn)

9.3 Inflammatory Ulcerative Colitis

9.3.1 Overview

9.3.2 North America Inflammatory Ulcerative Colitis Market Revenue and Forecasts to 2027 (US$ Mn)

9.4 Crohn's Disease

9.4.1 Overview

9.4.2 North America Crohn's Disease Market Revenue and Forecasts to 2027 (US$ Mn)

9.5 Irritable Bowel Syndrome

9.5.1 Overview

9.5.2 North America Irritable Bowel Syndrome Market Revenue and Forecasts to 2027 (US$ Mn)

9.6 Gastroenteritis

9.6.1 Overview

9.6.2 North America Gastroenteritis Market Revenue and Forecasts to 2027 (US$ Mn)

9.7 Celiac Disease

9.7.1 Overview

9.7.2 North America Celiac Disease Market Revenue and Forecasts to 2027 (US$ Mn)

9.8 Others

9.8.1 Overview

9.8.2 North America Others Market Revenue and Forecasts to 2027 (US$ Mn)

10. North America Gastrointestinal Drugs Market Analysis – By Distribution Channel

10.1 Overview

10.2 North America Gastrointestinal Drugs Market, By Distribution Channel 2019-2027 (%)

10.2.1 North America Gastrointestinal Drugs Market Revenue and Forecasts to 2027, By Distribution Channel (US$ Mn)

10.3 Hospital Pharmacies

10.3.1 Overview

10.3.2 North America Hospital Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)

10.4 Retail Pharmacies

10.4.1 Overview

10.4.2 North America Retail Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)

10.5 Online Pharmacies

10.5.1 Overview

10.5.2 North America Online Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)

11. Gastrointestinal Drugs Market Revenue and Forecasts To 2027 – Geographical Analysis

11.1 North America Gastrointestinal Drugs Market Revenue and Forecasts To 2027

11.1.1 Overview

11.1.2 North America: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)

11.1.3 North America: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)

11.1.4 North America: Gastrointestinal Drugs Market, by Route of Administration, 2018–2027 (USD Million)

11.1.5 North America: Gastrointestinal Drugs Market, by Application, 2018–2027 (USD Million)

11.1.6 North America: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)

11.1.7 North America: Gastrointestinal Drugs Market, by Country, 2019 & 2027 (%)

11.1.8 US: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)

11.1.8.1 US: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)

11.1.8.2 US: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)

11.1.8.3 US: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)

11.1.8.4 US: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)

11.1.8.5 US: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)

11.1.9 Canada: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)

11.1.9.1 Canada: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)

11.1.9.2 Canada: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)

11.1.9.3 Canada: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)

11.1.9.4 Canada: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)

11.1.9.5 Canada: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)

11.1.10 Mexico: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)

11.1.10.1 Mexico: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)

11.1.10.2 Mexico: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)

11.1.10.3 Mexico: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)

11.1.10.4 Mexico: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)

11.1.10.5 Mexico: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)

12. Impact of COVID-19 Pandemic on North America Gastrointestinal drugs Market

12.1 North America: Impact Assessment of COVID-19 Pandemic

13. Company Profiles

13.1 Johnson and Johnson Services, Inc.

13.1.1 Key Facts

13.1.2 Business Description

13.1.3 Products and Services

13.1.4 Financial Overview

13.1.5 SWOT Analysis

13.1.6 Key Developments

13.2 Bausch Health

13.2.1 Key Facts

13.2.2 Business Description

13.2.3 Products and Services

13.3.1 Financial Overview

13.3.2 SWOT Analysis

13.3.3 Key Developments

13.4 AbbVie Inc.

13.4.1 Key Facts

13.4.2 Business Description

13.4.3 Products and Services

13.4.4 Financial Overview

13.4.5 SWOT Analysis

13.4.6 Key Developments

13.5 LEXICON PHARMACEUTICALS, INC

13.5.1 Key Facts

13.5.2 Business Description

13.5.3 Products and Services

13.5.4 Financial Overview

13.5.5 SWOT Analysis

13.5.6 Key Developments

13.6 Takeda Pharmaceutical Company Limited

13.6.1 Key Facts

13.6.2 Business Description

13.6.3 Products and Services

13.7.1 Financial Overview

13.7.2 SWOT Analysis

13.7.3 Key Developments

14. Appendix

14.1 Glossary of Terms

LIST OF TABLES

Table 1. North America Gastrointestinal drugs Market Revenue and Forecasts To 2027, By Drug Class (US$ Mn)

Table 2. North America Gastrointestinal Drugs Market Revenue and Forecasts To 2027, By Route of Administration (US$ Mn)

Table 3. North America Gastrointestinal Drugs Market Revenue and Forecasts To 2027, By Application (US$ Mn)

Table 4. North America Gastrointestinal Drugs Market Revenue and Forecasts To 2027, By Distribution Channel (US$ Mn)

Table 5. North America Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)

Table 6. North America Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 7. North America Gastrointestinal Drugs Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 8. North America Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

Table 9. US Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)

Table 10. US Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 11. US Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)

Table 12. US Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

Table 13. Canada Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)

Table 14. Canada Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 15. Canada Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)

Table 16. Canada Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

Table 17. Mexico Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)

Table 18. Mexico Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 19. Mexico Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)

Table 20. Mexico Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

Table 21. Glossary of Terms, Gastrointestinal Drugs Market

LIST OF FIGURES

Figure 1. Gastrointestinal Drugs Market Segmentation

Figure 2. North America Gastrointestinal Drugs Market Overview

Figure 3. Acid Neutralizers Segment Held Largest Share of Product in Gastrointestinal Drugs Market

Figure 4. US is Expected to Show Remarkable Growth During the Forecast Period

Figure 5. North America Gastrointestinal Drugs Market - Leading Country Markets (US$ Mn)

Figure 6. Gastrointestinal Drugs Market - North America PEST Analysis

Figure 7. Gastrointestinal Drugs Market Impact Analysis of Drivers and Restraint

Figure 8. North America Gastrointestinal Drugs market – Revenue Forecasts and Analysis – 2019- 2027

Figure 9. North America Gastrointestinal Drugs Market, By Drug Class 2019 & 2027 (%)

Figure 10. North America Acid Neutralizers Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 11. North America Antidiarrheal and Laxatives Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 12. North America Anti-Inflammatory Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 13. North America Antiemetic and Antinauseants Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 14. North America Biologics Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 15. North America Anti-Inflammatory Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 16. North America Gastrointestinal Drugs Market, by Route of Administration 2019 & 2027 (%)

Figure 17. North America Oral Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 18. North America Parenteral Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 19. North America Gastrointestinal Drugs Market, by Application 2019 & 2027 (%)

Figure 20. North America Inflammatory Ulcerative Colitis Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 21. North America Crohn's Disease Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 22. North America Irritable Bowel Syndrome Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 23. North America Gastroenteritis Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 24. North America Celiac Disease Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 25. North America Others Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 26. North America Gastrointestinal Drugs Market, by Distribution Channel 2019 & 2027 (%)

Figure 27. North America Hospital Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 28. North America Retail Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 29. North America Online Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 30. North America: Gastrointestinal Drugs Market, by Key Country – Revenue (2019) (USD Million)

Figure 31. North America Gastrointestinal Drugs Market Revenue and Forecast to 2027 (USD Million)

Figure 32. North America: Gastrointestinal Drugs Market, by Country, 2019 & 2027 (%)

Figure 33. US: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)

Figure 34. Canada: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)

Figure 35. Mexico: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)

Figure 36. Impact of COVID-19 Pandemic on Gastrointestinal Drugs market in North American Countries

The List of Companies - North America Gastrointestinal Drugs Market

Johnson and Johnson Services, Inc.
Bausch Health
AbbVie Inc
LEXICON PHARMACEUTICALS, INC
Takeda Pharmaceutical Company Limited

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
Validates and strengthens in-house secondary research findings
Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

Industry participants: VPs, business development managers, market intelligence managers and national sales managers
Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.